Cell Therapeutics (CTIC) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Cell Therapeutics (CTIC)

CTIC 9.090

0.0%

Jun 26 5:00 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

From: Ian@SI	6/20/2006 12:00:38 PM
	of 946

They finally found their field of expertise: giving good presentations. :-( SEATTLE, June 20 /PRNewswire-FirstCall/ -- Cell Therapeutics, Inc. (CTI) (Nasdaq: CTIC; MTAX) recently presented preclinical and clinical data on XYOTAX(TM) (paclitaxel poliglumex) at the 46th Annual AFI (Associazione Farmaceutici Industria) Symposium in Rimini, Italy. The posters presented received awards for innovation and quality of scientific content. "The recognition these posters received underscores the high quality of research being done at our Bresso, Italy facility," stated James A. Bianco, M.D., President and CEO of CTI. CTI presented preclinical and clinical data on the gender effect and role of estrogen on XYOTAX pharmacokinetics (PK). One of the main proteolytic enzymes involved in degradation of the polyglutamate polymer is cathepsin B, whose expression is upregulated by estrogens. [SNIP]

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next